Welcome and Opening Remarks

10:30

Jill Biden, EdD  
First Lady of the United States

The Honorable Michael N. Castle*  

Mary Woolley*  
President and CEO, Research!America

Outsmarting a Global Health Threat: What will it take to keep AMR at bay?

10:45

Each year in the United States, more than 2 million people become infected with bacteria that are resistant to antibiotics, and at least 23,000 die as a result of these infections. Globally, an estimated 700,000 deaths per year are attributed to antimicrobial resistance (AMR). The WHO has declared that AMR is one of the top ten global public health threats facing humanity. Combating AMR requires innovation, not just to develop treatments that replace those compromised by AMR, but to slow the trajectory of AMR as much as possible, saving lives and creating space for those new treatments to come to fruition. This interactive roundtable discussion will focus on the latter imperative. What are the strategies that fall under the umbrella of AMR “stewardship?” Can we do more to slow the pace of resistance, and if so, how? How high are the stakes? How is stewardship success measured? What is the outlook absent new strategies and faster development of antimicrobial treatments?

Alok Patel, MD  
Pediatric Hospitalist, Lucile Packard Children’s Hospital; Special Correspondent, ABC News; Pediatric Content Advisor, Medscape; Host, NOVA Now Podcast, PBS

Stefano Bertuzzi, PhD, MPH  
CEO, American Society for Microbiology

Amanda Jezek  
Senior Vice President, Public Policy and Government Relations, Infectious Diseases Society of America

Santiago Gonzalez, MPH  
Senior Policy Advisor, Senator Michael Bennet (D-CO)

Alok Patel, MD  
Pediatric Hospitalist, Lucile Packard Children’s Hospital; Special Correspondent, ABC News; Pediatric Content Advisor, Medscape; Host, NOVA Now Podcast, PBS

Stefano Bertuzzi, PhD, MPH  
CEO, American Society for Microbiology

Elizabeth Dodds Ashley, PharmD, MHS, FCCP, BCPS  
Associate Professor of Medicine with the Division of Infectious Diseases and International Health, Duke University School of Medicine

Rita Livadas, PharmD  
Director of Public Affairs, BD

12:00  
Living with a Rare Disease: Cystic Fibrosis

Gunner Esiason  
Patient Advocate, Boomer Esiason Foundation

12:20  
Diagnosing Rare Diseases: A Parent’s Journey

Christina Hartman  
Vice President of External Affairs, The Assistance Fund

* Denotes Research!America Board Member
**Faster Rare Disease Progress is Within our Reach**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 12:30 | Mary Woolley*  
President and CEO, Research!America | Emil Kakkis, MD, PhD  
Chief Executive Officer and President, Ultragenyx Pharmaceutical Inc. |

**Envision360: It Takes an Ecosystem**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 12:45 | Michael Ybarra, MD  
Vice President of Advocacy and Strategic Alliances and  
Chief of Medical Affairs, PhRMA |          |

**Fireside Chat: The Research Behind Healthcare Excellence**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 12:51 | David Meyers, MD  
Acting Director, Agency for Healthcare Research and Quality | Lisa Simpson, MB, BCh, MPH, FAAP  
President and CEO, AcademyHealth |

**U.S. Science and Technology on the Front Lines**

The audience will join renowned leaders in science and technology to take a clear-eyed look at efforts to equip our nation with the S&T capabilities needed to out-innovate existential threats and stay globally competitive. Will current policy efforts to bolster U.S. S&T come to fruition? How do we ensure our nation can continue to successfully compete in the global economy while collaborating internationally to maximize S&T progress? The conversation will fully engage the audience on these critical questions and more.

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 1:30  | Sudip Parikh, PhD*  
Chief Executive Officer; Executive Publisher, Science Family of Journals, American Association for the Advancement of Science | Sethuraman Panchanathan, PhD  
Director, National Science Foundation  
Mikael Dolsten, MD, PhD*  
Chief Scientific Officer and President, Worldwide Research, Development, and Medical, Pfizer Inc  
Kaye Husbands Fealing, PhD  
Dean, Ivan Allen College of Liberal Arts, Georgia Institute of Technology  
Marcia McNutt, PhD  
President, National Academy of Sciences |

**Fireside Chat: Innovation Amplified: ARPA-H**

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Speakers</th>
</tr>
</thead>
</table>
| 2:40  | Hallie Jackson  
Senior Washington Correspondent, NBC News; Host, MSNBC's "Hallie Jackson Reports" | Francis Collins, MD, PhD  
Director, National Institutes of Health  
Eric Lander, PhD  
Director, Office of Science and Technology Policy; Science Advisor to the President |

*Denotes Research!America Board Member*
Chronic diseases and conditions have figured prominently into the COVID-19 pandemic, increasing the risk associated with and the toll the coronavirus has taken on Americans and populations across the globe. Beyond COVID-19, the human and fiscal costs of this constellation of health threats is staggering: according to the Milken Foundation, the annual economic impact on the U.S. of the seven most common chronic diseases is estimated to be $1.3 trillion, which could grow to approximately $6 trillion by 2050.

This discussion will focus on public and private sector-fueled progress against lupus and Alzheimer’s, two diseases emblematic of the challenges posed by chronic conditions, shedding light on how far we’ve come and how far we have yet to go to defeat them. What are the most promising developments against lupus and Alzheimer’s disease? What is the significance of the regulatory landscape? What role do patients play in determining the direction of progress against these threats?

* Denotes Research!America Board Member
12:45  
**Fireside Chat: Prevent, Intercept, Eradicate: Reimagining Medical Progress**

**Ellie Dehoney**  
Vice President, Policy and Advocacy, Research!America

**William N. Hait, MD, PhD**  
Global Head, Johnson & Johnson Global External Innovation

1:00  
**Writing a Compelling Opinion Piece**

**John Siniff**  
Executive Vice President, Subject Matter; Former Opinion Editor, USA Today

2:30  
**Researcher to Researcher: A Fireside Chat with Dr. Anthony Fauci**

**Alexandra Colón-Rodríguez, PhD**  
Postdoctoral Scientist, Neurobiology, Physiology, and Behavior, University of California Davis

**Anthony S. Fauci, MD**  
Director, National Institute of Allergy and Infectious Diseases, NIH

2:40  
**Flash Talks Competition**

Featuring young scientists from academia and industry, judged by a panel of science communicators.

**Judges:**

**Dana Acton**  
Director, Science Policy and Legislative Affairs, American Association for Cancer Research (AACR)

**Kafui Dzirasa, MD, PhD**  
K. Ranga Rama Krishnan Endowed Associate Professor of Psychiatry and Behavioral Sciences, Duke University Medical Center

**Joel Beetsch, PhD**  
Vice President of Corporate Affairs, Eisai, Inc.

**Lauren Powell, MPA, PhD**  
President & CEO, The Equitist, LLC; Vice President, US Health Equity & Community Wellness, Takeda Pharmaceuticals

**Andrea Morgan**  
Graduate Research Assistant, Behavioral and Systems Neuroscience Program, Oregon Health & Science University

**Andrea Colón-Rodríguez, PhD**  
Postdoctoral Scientist, Neurobiology, Physiology, and Behavior, University of California Davis

**James Quinn, PhD**  
Neurology Research Fellow, Alzheimer's Clinical & Translational Research Unit (ACTRU), Massachusetts General Hospital and Harvard Medical School

**Faiza Siddiqui, PhD**  
Research Associate, Department of Internal Medicine, University of South Florida

**Competitors:**

**Salvatore Aiello**  
MD/PhD Candidate, Rosalind Franklin University of Medicine & Science

**Sarah Grace Dennis-Little, PhD**  
Postdoctoral Scholar, Department of Surgery, Medical University of South Carolina

**Denotes Research!America Board Member**
DAY 3-Defining the Path Forward

September 15

10:45
**The Challenge and Imperative of Advancing Diversity in Cancer Clinical Trials**

*Jeff Allen, PhD*
President and CEO, Friends of Cancer Research

*Peter C. Adamson, MD*
Global Head, Oncology Development and Pediatric Innovation, Sanofi

11:00
**Can We Truly Conquer Cancer?**

The participants in this discussion will explore the path to progress against cancer from several different vantage points. Bringing together representatives from the patient community, the federal government, academia, and industry, the discussion will highlight the roles the public and private sector play in cancer-focused discovery, development, and delivery; hone in on the extraordinary potential inherent in breakthroughs such as immunology and CRISPR, and what those leaps in progress mean for the spectrum of cancer threats; shed light on the challenges that have rendered progress elusive against some forms of the disease such as glioblastoma and pancreatic cancer; and look at ways the horizon may be shifting (e.g. the possibility of new platforms that enable progress against multiple forms of cancer at once; the role of new clinical trial designs) as the fight to overcome cancer continues.

*Jeff Allen, PhD*
President and CEO, Friends of Cancer Research

*Ned Sharpless, MD*
Director, National Cancer Institute, NIH

*Julia Beaver, MD*
Chief of Medical Oncology, Oncology Center of Excellence; Deputy Director (Acting), Office of Oncologic Diseases, Center for Drug Evaluation and Research, FDA

*John Carpten, PhD*
Professor and Chair, Department of Translational Genomics; Director, Institute for Translational Genomics, Keck School of Medicine, University of Southern California

*Jacqueline Corrigan-Curay, JD, MD*
Principal Deputy Center Director, Center for Drug Evaluation and Research, FDA

*Lisa Lacasse*
President, American Cancer Society Cancer Action Network

*David Reese, MD*
Executive Vice President, Research and Development, Amgen

12:30
**Diversity, Equity, & Inclusion: Tracking Progress and Measuring Success**

The roundtable participants — with audience input and a focus on the health-focused R&D workforce and workplace — will share strategies for advancing and evaluating diversity, equity, and inclusion (DEI). What are the best practices for advancing workforce and workplace DEI? Are there approaches that appeared to hold promise, but have proven ineffective? Are current definitions of DEI too broad or too narrow to promote the wellbeing of individuals across the R&D workforce? What quantitative and qualitative measures accurately capture DEI progress? What are the key attributes of a diverse, equitable and inclusive workforce and workplace?
Jessica Bylander  Senior Editor and Correspondent, Health Affairs

Thomas LaVeist, PhD  Dean and Weatherhead Presidential Chair in Health Equity, Tulane University School of Public Health and Tropical Medicine

Chetana Rao, PhD  Head, Site Strategy & Operations, Redwood City, San Francisco, Bristol Myers Squibb

Robert Sellers, PhD  Vice Provost for Equity & Inclusion and Chief Diversity Officer; Charles D. Moody Collegiate Professor of Psychology, University of Michigan

Esther C. Nolton, PhD, MEd  Program Officer, Evaluation and Analysis, Patient-Centered Outcomes Research Institute

Keith Yamamoto, PhD  Special Advisor to the Chancellor for Science Policy and Strategy, University of California San Francisco

1:30  ENVISION 360: Defining Success in Clinical Trial Diversity

Rachael Fones  Director, Government & Public Affairs, IQVIA

1:45  A View from the Problem Solvers Caucus

Jenny Luray  Vice President of Strategy and Communications, Research!America

The Honorable Josh Gottheimer  U.S. Representative (D-NJ-05)

The Honorable Charlie Dent*  Executive Director & Vice President, The Aspen Institute, Senior Policy Advisor, DLA Piper LLP, U.S. Representative, 2005-2018

2:00  COVID-19 Vaccines: A Conversation with FDA’s Peter Marks

Amy Comstock Rick, JD*  President and CEO, Food and Drug Law Institute

Peter Marks, MD  Director, Center for Biologics Evaluation & Research, FDA

2:15  Envision360: Global Threats Cross Borders: Dengue Fever

Derek Wallace, MBBS  Vice President and Global Dengue Program Head, Vaccine Business Unit, Takeda Pharmaceuticals

3:00  ENVISION360: Championing Self-Care

Laurie Hernandez  Olympic Gymnastics Champion and One Mind Ambassador

3:06  Mental Health is Health: An Integrated Agenda for Public Health Progress

The Honorable Patrick J. Kennedy  Former U.S. Representative (D-RI), Founder, Kennedy Forum

* Denotes Research!America Board Member
What’s important in health care? Medical and public health progress that bring about safe and effective solutions; affordability for individual patients and for our healthcare system as a whole; access to the benefits of medical progress; and health equity, which depends on progress, affordability, and access, are certainly cornerstones of an effective health care system. Looking at prescription drugs as one piece of the health care puzzle, this interactive roundtable discussion will explore the challenges, imperatives, and options for simultaneously advancing progress, affordability, access, and equity.

Mark McClellan, MD, PhD*
Director, Robert J. Margolis Center for Health Policy, Duke University; Former Administrator, CMS, 2004-2006; Former Commissioner, FDA, 2002-2004

Peter Pronovost, MD, PhD
Chief Quality & Clinical Transformation Officer, University Hospitals; Professor, Department of Anesthesiology and Critical Care Medicine, School of Medicine and School of Nursing, Case Western Reserve University

Gary Puckrein, PhD
President and Chief Executive Officer, National Minority Quality Forum

Mark Reisenauer
President, Astellas Pharma US

Cynthia Zagieboylo*
President and Chief Executive Officer, National MS Society

* Denotes Research!America Board Member

THANK YOU TO OUR SPONSORS!

LEAD SPONSOR

Pfizer

FORUM PARTNER SPONSORS

Horizon Sanofi

ROUNDTABLE SPONSORS

AdvaMed
Astellas
BD
GlaxoSmithKline
Lilly
pcori
Regeneron

Fireside Chat Sponsors

Alnylam
Colgate
Eisai
Johnson & Johnson

Flash Talks Sponsor

Johnson & Johnson

Daily Host

Special Speaker Series Sponsors

Workshop Sponsor

Envision360 Sponsors

Updated as of 9/8/21

The Research!America alliance advocates for science, discovery, and innovation to achieve better health for all.